{"entity":{"id":"nct03937141","kind":"trial","name":"Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer","aka":[],"tldr":"A phase 2 trial of ADU-S100 in Head and neck squamous cell carcinoma, run by Chinook Therapeutics, Inc. (formerly Aduro), recorded as terminated on the registry.","summary":"Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer is a phase 2 interventional study registered as NCT03937141 by Chinook Therapeutics, Inc. (formerly Aduro), with 16 participants recorded, started 2019-08-26 and due to reach its primary completion in 2021-05-10. Interventions recorded: ADU-S100. Conditions recorded: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer.\n\nLinked to the drug ADU-S100 because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03937141","url":"https://clinicaltrials.gov/study/NCT03937141"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["adu-s100"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03937141","phase":"2","setting":"A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer","sponsor":"Chinook Therapeutics, Inc. (formerly Aduro)","enrolled":16,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03937141/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"adu-s100","kind":"drug","name":"ADU-S100 (MIW815)","route":"/drugs/adu-s100/"}]}}